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Neuromyelitis optica (NMO) is an inflammatory auto-
immune disease that affects the central nervous system 
(CNS) associated to significant neurologic disability1,2. For 
many decades, NMO was considered a variant of multiple 
sclerosis (MS), characterized by recurrent bilateral optic 
neuritis and transverse myelitis occurring concomitantly 
or apart in time, and without evidence of disease outside 
the optic nerves and the spinal cord3. Nowadays, studies 
ABSTRACT
Although neuromyelitis optica (NMO) is known to be a more severe disease than relapsing-remitting multiple sclerosis (RRMS), few studies 
comparing both conditions in a single center have been done. Methods: Comparison of our previously published cohort of 41 NMO patients 
with 177 RRMS patients followed in the same center, from 1994 to 2007. Results: Mean age of onset was 32.6 for NMO and 30.2 for RRMS 
(p=0.2062) with mean disease duration of 7.4 years for NMO and 10.3 years for RRMS. Patients with NMO had a higher annualized relapse 
rate (1.0 versus 0.8, p=0.0013) and progression index (0.9 versus 0.6, p<0.0001), with more patients reaching expanded disability status scale 
(EDSS) 6.0 (39 versus 17%, p=0.0036). The odds ratio for reaching EDSS 6.0 and being deceased due to NMO in comparison to RRMS were, 
respectively, 3.14 and 12.15. Conclusion: Patients with NMO have a more severe disease than patients with RRMS, including higher risk of 
dying of a demyelinating disease.
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RESUMO
Embora a neuromielite óptica (NMO) seja reconhecida como mais grave que a esclerose múltipla remitente recorrente (EMRR), existem 
poucos estudos comparando as duas doenças em um único centro. Métodos: Comparação de nossa coorte publicada de 41 pacientes com 
NMO com 177 pacientes com EMRR seguidos no mesmo centro, de 1994 a 2007. Resultados: A média de idade inicial foi de 32,6 anos em NMO 
e 30,2 anos em EMRR (p=0,2062), com tempo médio de doença de 7,4 anos para NMO e 10,3 anos EMRR. Pacientes com NMO apresentaram 
maior taxa anualizada de surtos (1,0 versus 0,8, p=0,0013) e índice de progressão (0,9 versus 0,6, p<0,0001), com mais pacientes atingindo 
EDSS 6,0 (39 versus 17%, p=0,0036). Os riscos relativos de se alcançar 6,0 EDSS e falecer em decorrência de NMO em comparação com 
EMRR, foram, respectivamente, 3,14 e 12,15. Conclusão: Pacientes com NMO têm uma doença mais grave do que os pacientes com EMRR, 
incluindo maior risco de morrer de uma doença desmielinizante.
Palavras-Chave: neuromielite óptica, esclerose múltipla, doenças desmielinizantes, fatores de risco.
indicate that NMO is a distinct disease from MS4, with 
nearly 90% of patients presenting a relapsing remitting 
course and half of them exhibiting brain lesions on mag-
netic resonance imaging2,5. 
Although NMO is frequently cited to have a more severe 
clinical course than relapsing-remitting MS (RRMS), few di-
rect head-to-head studies involving both diseases in a sin-
gle center scenario have been done6,7. We recently published 
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 We collected demographic and clinical data of all pa-
tients that met the inclusion criteria. To avoid bias due to 
disease duration, we divided the expanded disability status 
scale (EDSS) on last follow-up visit and total number of re-
lapses by the total time of disease (in years), thus using the 
progression index (PI) and annualized relapse rate (ARR) to 
evaluate disease progression and severity when comparing 
the groups of patients. Reaching an EDSS score of 6.0 was 
considered a hard clinical endpoint of disease severity, as this 
confers severe disability and impacts on social life. Patients in 
this study received regular preventive therapies recommend-
ed and available for their diagnosis (RRMS or NMO) at the 
time they were seen, which included, but were not restricted 
to, interferon beta, glatiramer acetate, corticosteroids, cyclo-
phosphamide, methotrexate, azathioprine and intravenous 
immunoglobulin, with the exception of five patients with 
NMO and two with RRMS that received no treatment apart 
of pulse intravenous steroids for the treatment of relapses.
The statistical analysis was performed using GraphPad 
Prism version 5.0 (GraphPad Software Incorporated®). 
Unpaired t test or Mann-Whitney tests were used when 
comparing two groups, according to results on Kolmogorov-
Smirnov normality test; χ2 or Fisher’s exact test when appro-
priate. Reaching an EDSS score of 6 was considered a clini-
cal endpoint of disease severity, as this confers moderate to 
severe disability and impacts on social life. Building a pre-
cise Kaplan-Meier curve for estimating the time to assign-
ment of EDSS 6.0, we considered a period of 100 months (8.3 
years), which corresponds to the 95% confidence interval of 
total disease duration time for the patients with NMO. Data 
are presented as mean±standard deviation (SD), and signif-
icance was set at p<0.05. Approval by the Internal Review 
Board of the UNIFESP was obtained prior to study onset.
RESULTS 
One hundred and seventy seven patients that debuted with 
RRMS fulfilled the inclusion criteria and were selected to be 
compared to the 41 patients with NMO previously reported2. 
At the moment of data collection, 129 patients were still cat-
egorized as RRMS and 48 (27%) had evolved to the secondary 
progressive clinical phase of MS. No differences in age at onset 
and female to male ratios were found between MS and NMO 
patients. When comparing time elapsed from first relapse to 
evaluation at our center, patients with NMO were referred 
nearly within half the time than patients with MS, respectively, 
37.2 (±47.4) versus 69.0 (±86.6) months. Patients with MS had a 
clear predominant Caucasian ethnic background, and patients 
with NMO had more African (including Brazilian Mulatto) and 
Asian ancestry background (Table). 
Patients with NMO had higher EDSS on first and 
last appointment, higher PI and ARR, and a greater 
a series of 41 patients with recurrent NMO followed at the 
Neuroimmunology Clinic of the Universidade Federal de São 
Paulo (UNIFESP), which showed that incomplete recovery 
from relapses was the main clinical predictor of future neuro-
logic disability and azathioprine solely or in association with 
prednisone was able to halt relapses and disability progres-
sion in 76% of the patients2,8. In order to better understand 
the clinical differences between NMO and MS, we compared 
this cohort of 41 patients with recurrent NMO2 with patients 
followed for RRMS in the same center.
METHODS
The Neuroimmunology Clinic of the UNIFESP is a tertiary 
care center focused on caring for patients with multiple scle-
rosis and other demyelinating diseases, established in 1994. 
Since then, the center keeps a database containing all clin-
ical, laboratory, radiological and therapeutic information of 
the patients. 
Cohort
We retrospectively compared our previously pub-
lished cohort of 41 patients with recurrent NMO with 177 
patients with RRMS followed in the same center, from 
February 1994 to December 2005 for RRMS9 and July 2007 
for NMO2. Regular appointments were scheduled every 
three months in the first year of follow-up and every six 
months afterwards, unless a relapse or drug adverse event 
incited an urgent evaluation. All patients were seen and 
examined by the same physicians along follow-up (DBB, 
NAS, EMLO and AAG), and clinical and radiological in-
formation were retrieved from each patient’s file and im-
puted to a computer database in Microsoft’s Excel files 
in 2005 and 2007 for RRMS and NMO, respectively. These 
databases were selected for this specific analysis as they 
were already completed and represent patients from the 
same time period in a single center setting.
Inclusion criteria for this analysis were: fulfillment of 
Wingerchuk NMO criteria as per 20067 for patients with re-
current NMO, and fulfillment of McDonald 2001 criteria 
for RRMS10. All patients included had at least two appoint-
ments and follow-up longer than six months. Patients with 
relapsing remitting MS seen before the publication of the 
McDonald criteria, i.e., seen before 2001 and thus classified 
by the Poser criteria11, had their files and magnetic resonance 
images (MRI) reports reviewed for diagnosis reassurance. 
Given that it is presumed there is no degenerative process in 
NMO12-14 and thus patients with NMO do not present with a 
progressive clinical course12, patients with primary progres-
sive forms of MS (primary progressive or relapsing progres-
sive) were excluded in order to perform a more appropriate 
comparison between MS and NMO.
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proportion of patients with NMO reached EDSS 6.0 dur-
ing follow-up than patients with RRMS (Table and Figure). 
Furthermore, even with shorter disease duration, the 
odds ratio for reaching EDSS 6.0 and dying due to NMO 
in comparison to MS were, respectively, 3.14 (95%CI 
1.496–6.576, p=0.0036) and 12.15 (95%CI 2.267–65.140), 
p=0.0017. There were no differences in age of onset and 
female to male ratio between patients with MS and 
NMO (Table).
Thirty-six patients with NMO received immunomodu-
latory or immunosuppressive treatments as previously de-
scribed8. All but two patients with RRMS described here 
used at least one approved immunomodulatory drug (be-
tainterferon 1a, betainterferon 1b or glatiramer acetate), 
44 patients changed treatment drug once, and 53 patients 
switched therapies 3 or more times. Reasons from switching 
drug in RRMS could be either adverse effects or failure to re-
spond to a specific regimen, and patients were switched ei-
ther from one betainterferon formulation to another, from 
betainterferon to glatiramer acetate or vice-versa, or were 
offered monthly IV cyclophosphamide in severe cases.
DISCUSSION
Patients with NMO presented in this study had clear-
ly a more severe disease than patients with MS that de-
buted as RRMS, disclosed not only by PI and ARR com-
parison, but also by EDSS on first and last evaluations. 
The Kaplan-Meier estimates expose that more patients 
with NMO have a higher risk and a shorter time to 
reach EDSS 6.0, which, associated to a higher odds ra-
tio of being deceased, reinforces the more severe prog-
nosis of patients with NMO than patients with an initial 
presentation of RRMS. Although patients with NMO had 
shorter disease duration, this does not affect the anal-
ysis through PI an ARR, as data have been divided for 
the total years of disease to allow proper comparisons. 
Considering that relapse rate and incomplete recovery 
from relapses are the key factors correlated with future 
disability in NMO2,15, the association of higher ARR and 
PI in NMO than in RRMS strengthens the need to early 
control of relapse recurrence in patients with NMO.
Past series encompassing patients with NMO have 
shown a mean age of first symptom of 36 years old (±4.8) 
and female to male ratio ranging from 2.4:1 to 36:11,12,16-25, 
which is distinct from the present results. Interestingly, 
when these series are arranged by date, the most recent 
works presented results similar to ours16-19, while stud-
ies published before 2007–2008 presented patients with 
an older age of onset and more marked female predomi-
nance1,12,20-25. It is not clear why these differences exist, 
and we hypothesize that the increase in knowledge on 
the disease’s pathophysiology4, brain and spinal cord im-
aging2,5,26, treatment possibilities8,27-29 and broad propaga-
tion of the disease’s previous1 and current diagnostic cri-
teria7,29 might have contributed for a wider selection of 
patients in the later studies. Therefore, the present study 
suggests that, concerning age of onset and female:male 
ratio, NMO patients might not differ much from RRMS, 
and this demographic information should not influence 
the weighting of one diagnosis over another.
Our study reinforces previous knowledge that the 
prevalence of NMO is higher in non-Caucasians, as op-
posed to MS. These differences might be explained by dif-
ferent genetic background between these two patient’s popu-
lation, as the DRB1*1501 HLA haplotype is not associated to 
NMO as it is in MS18,30,31. Furthermore, Brazilian collaboration 
NMO MS
p-value
(n=41) (n=177)
Age of onset (years)
Sex (F:M)
32.6 (±11.5)
2.4:1
30.2 (±10.5)
3.8:1
0.2062
0.3429
Ethnicity <0.0001
Caucasian 18 (44%) 127 (72%)
African 11 (24%) 5 (3%)
Asian 2 (5%) 0 (0%)
Mulatto 10 (24%) 45 (25%)
Disease duration (years) 7.4 (±4.9) 10.3 (±7.6) 0.0239
Time to first evaluation (months) 37.2 (±47.4) 69.0 (±86.6) 0.0368
EDSS first evaluation 3.9 (±1.7) 2.4 (±2.0) <0.0001
EDSS last evaluation 5.2 (±2.7) 3.6 (±2.7) 0.0013
Annualized relapse rate 1.0 (±0.8) 0.8 (±0.9) 0.0079
Progression index 0.9 (±0.7) 0.6 (±1.0) <0.0001
Patients reaching EDSS 6, n (%) 16 (39%) 30 (17%) 0.0036
Patients deceased 5 (12%) 2 (1%) 0.0017
Table. Demographics and disease evolution of patients with NMO and MS.
NMO: neuromyelitis optica; MS: multiple sclerosis (patients that debuted as relapsing remitting MS), 48 had evolved to a secondary progressive MS along follow-up; 
EDSS: expanded disability status scale; annualized relapse rate: total number of relapses/disease duration; progression index: EDSS on last appointment/disease 
duration; time to first evaluation indicates the time elapsed between first symptom and first appointment at our center; F: female; M: male.
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studies have identified the HLA-DRB1*3 to be overrepresent-
ed in NMO18. In this same study, the low frequency of HLA-
DRB1*15 alleles was associated with the presence of long and 
central cord lesions at magnetic resonance18. Although these 
genetic differences might be associated with the non-Cauca-
sian predominance among patients with NMO, it is not yet 
clear whether they are related to the disease’s susceptibility 
or pathophysiology mechanisms.
An interesting data observed in this study is the short-
er time from symptom onset to first evaluation in our 
clinic, for patients with NMO in comparison to MS. The 
Neuroimmunology Clinic of the Universidade Federal de São 
Paulo is a referral center for demyelinating disease, and pa-
tients can schedule an appointment by free will or be sent by 
their primary care physician or neurologist. We presume that 
this shorter interval might be due to relapse severity, which 
impel the need for a specific diagnosis and prompt evalua-
tion at a specialized center. 
In addition to being a retrospective study, most patients 
evaluated in this analysis received immunomodulatory or 
immunosuppressive treatment, thus we cannot state that 
our results qualify as a natural history cohort comparison 
study between diseases. Nevertheless, as 29 patients with 
NMO received long term preventive treatment with azathio-
prine, an effective drug for halting relapses in 76%8,27, the dif-
ferences in severity between both diseases might have even 
been greater if both groups of patients did not have received 
any type of treatment along follow-up. 
Our data objectively expose that patients with NMO have a 
more severe disease than patients with RRMS, including high-
er risk of dying of a demyelinating disease. We therefore advo-
cate that patients with relapsing NMO should be candidates for 
early and appropriate immunosuppressive treatment in order to 
avoid relapses and the accumulation of neurological disability. 
Nonetheless, clinical trials addressing the real safety and efficacy 
of immunosuppressive drugs in NMO are mandatory.
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Figure. Kaplan-Meier curves for the probability to reach an 
EDSS score ≥6.0 for patients with relapsing remitting multiple 
sclerosis (dashed lines) and neuromyelitis optica (black lines).
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